COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome
复制标题
DOI：
10.3233/jnd-200520
复制
发表时间：
2020-01-01
影响因子：
3.3
通讯作者：
Govindarajan, Raghav
中科院分区：
文献类型：
--
作者：
Ramaswamy, Swathi Beladakere;Govindarajan, Raghav
这是一名在2020年大流行期间感染COVID-19的难治性重症肌无力患者，接受多种长期免疫抑制治疗的简短报告。她被隔离了14天，成功康复，没有任何并发症（没有肌无力加重或危重，没有COVID-19相关并发症），免疫抑制治疗没有改变。MG型新冠肺炎患者的治疗需要因地制宜。
This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She was quarantined for total of 14 days and recovered successfully without any complications (no myasthenia exacerbation or crisis, no COVID-19 related complications), with no changes to her immunosuppressive therapy. Treatment of MG patients with COVID-19 needs to be tailored to individual patient.